Lifeward Ltd. Files 8-K on Operations
Ticker: LFWD · Form: 8-K · Filed: Oct 16, 2025 · CIK: 1607962
Sentiment: neutral
Topics: 8-K, corporate-update, financials
TL;DR
Lifeward Ltd. (fka ReWalk) filed an 8-K on Oct 16, 2025, updating on financials.
AI Summary
Lifeward Ltd. (formerly ReWalk Robotics Ltd.) filed an 8-K on October 16, 2025, to report on its results of operations and financial condition. The company, incorporated in Israel and headquartered in Marlborough, MA, is involved in the orthopedic, prosthetic, and surgical appliances and supplies industry.
Why It Matters
This filing provides an update on Lifeward Ltd.'s financial performance and operational status, which is crucial for investors to assess the company's current health and future prospects.
Risk Assessment
Risk Level: low — This is a routine 8-K filing providing standard corporate information and updates, not indicating any immediate or significant risk.
Key Players & Entities
- Lifeward Ltd. (company) — Registrant
- ReWalk Robotics Ltd. (company) — Former company name
- Argo Medical Technologies Ltd. (company) — Former company name
- October 16, 2025 (date) — Date of earliest event reported
- 200 Donald Lynch Blvd. Marlborough, MA 01752 (address) — Principal executive offices
FAQ
What is the primary business of Lifeward Ltd.?
Lifeward Ltd. is in the business of orthopedic, prosthetic & surgical appliances & supplies, with SIC code 3842.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on October 16, 2025.
What were Lifeward Ltd.'s former names?
Lifeward Ltd. was formerly known as ReWalk Robotics Ltd. and prior to that, Argo Medical Technologies Ltd.
Where are Lifeward Ltd.'s principal executive offices located?
Lifeward Ltd.'s principal executive offices are located at 200 Donald Lynch Blvd., Marlborough, MA 01752.
What is the SEC file number for Lifeward Ltd.?
The SEC file number for Lifeward Ltd. is 001-36612.
Filing Stats: 679 words · 3 min read · ~2 pages · Grade level 11.9 · Accepted 2025-10-16 07:00:52
Key Financial Figures
- $6.2 million — minary revenue results of approximately $6.2 million for the quarter ended September 30, 202
- $5.8 million — expenses in the range of approximately $5.8 million to $5.9 million. The Company's cash and
- $5.9 million — range of approximately $5.8 million to $5.9 million. The Company's cash and cash equivalent
- $2.0 million — of September 30, 2025 was approximately $2.0 million. These unaudited, preliminary amounts h
Filing Documents
- zk2533854.htm (8-K) — 39KB
- image0.jpg (GRAPHIC) — 57KB
- 0001178913-25-003509.txt ( ) — 245KB
- rwlk-20251016.xsd (EX-101.SCH) — 4KB
- rwlk-20251016_lab.xml (EX-101.LAB) — 21KB
- rwlk-20251016_pre.xml (EX-101.PRE) — 16KB
- zk2533854_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. Preliminary Financial Results On October 16, 2025, Lifeward Ltd. (the "Company") announced its preliminary revenue results of approximately $6.2 million for the quarter ended September 30, 2025 and its preliminary U.S. GAAP operating expenses in the range of approximately $5.8 million to $5.9 million. The Company's cash and cash equivalents as of September 30, 2025 was approximately $2.0 million. These unaudited, preliminary amounts have been prepared by and are the responsibility of management. These amounts are based upon information available to management as of the date of this Current Report on Form 8-K and subject to completion of customary quarter-end close procedures and financial review that could result in changes to the amounts. Furthermore, these amounts do not present all information necessary for an understanding of the Company's financial condition as of September 30, 2025 or its results of operations as of such date. The Company's independent registered public accounting firm, Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global ("EY"), has not audited, reviewed, compiled or performed any procedures with respect to these preliminary financial results and, accordingly, EY does not express an opinion or any other form of assurance with respect thereto. The Company's actual results for the quarter ended September 30, 2025 will be included in its Quarterly Report on Form 10-Q and may differ materially from the above estimate. The Company's cash, cash equivalent and short-term investment balance as of September 30, 2025 is approximately $2.0 million. The information disclosed in this Item 2.02 is being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference in any filing under the
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Lifeward Ltd. Dated: October 16, 2025 By: /s/ Almog Adar Name: Almog Adar Title: Chief Financial Officer